New treatments in early age-related macular degeneration

5 September 2012
Volume 13, Issue 3
AMD

This article reviews the various treatment options available as prophylactic therapy for early AMD.

Introduction

Age-related macular degeneration (AMD) is the leading cause of blindness amongst the elderly in the western world. An estimated 30% of people aged 75 years or older show at least the early manifestations of AMD, which consists of yellow deposits (drusen) and/or pigment clumps. In the UK, there are 25 000 new cases of wet AMD each year and the current intravitreal anti-VEGF therapy costs 1% of the annual £9 billion NHS budget. Currently, there is no treatment to prevent progression of the earlier stages of AMD. Prevention is better than cure and there is ongoing research into finding a preventive therapy for this disease. This article reviews the various treatment options available as prophylactic therapy for early AMD.

Sign in to continue

Forgotten password?
Register

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

A message from Colin Davidson, College President.

AMD

Seek out cutting-edge clinical content to address new challenges, says Kieran Loft MCOptom.

This edition takes a look at the risk variants and genetic distribution of Age-related macular degeneration as well as topical ivermectin-metronidazole gel therapy for blepharitis caused by Demodex.